Full Press Release Details
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA)?
Did you purchase your shares in connection with the Company’s September 15, 2023 IPO?
Did you lose money in your investment in Neumora Therapeutics, Inc.?
Do you want to discuss your rights?
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
If you purchased or acquired Neumora stock, and/or would like to discuss your legal rights and options please visit Neumora Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
A lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired the stock of Neumora pursuant and/or traceable to the offering documents issued in connection with the initial public offering (“IPO”) held on or about September 15, 2023, inclusive, alleging violations of the Securities Act of 1933 against the Company and certain of its senior officers.
According to the lawsuit, Defendants made misrepresentations concerning risks and uncertainties known by the Company at the time of the IPO regarding the Phase Three Program for Navacaprant, its flagship drug candidate.
If you wish to serve as lead plaintiff for the Class, you must file papers by April 7, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP
Tags
neumora therapeutics
class action lawsuit